Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.
about
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapyKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaMelanoma: from mutations to medicineTargeting the apoptosis pathway in hematologic malignanciesmiR-15a and miR-16-1 in cancer: discovery, function and future perspectivesEmerging drugs for chronic lymphocytic leukaemia.Oblimersen for the treatment of patients with chronic lymphocytic leukemia.Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.G3139 (Genasense) in patients with advanced merkel cell carcinomaHigher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.The essential role of evasion from cell death in cancer.Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.Advances in the treatment for haematological malignancies.Antisense oligonucleotides: from design to therapeutic application.Molecular mediators of cell death in multistep carcinogenesis: a path to targeted therapy.Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia.A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML.Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Bortezomib in mantle cell lymphoma.Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.Personalized medicine in CLL: current status and future perspectives.Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.Mimicking the BH3 domain to kill cancer cellsSmall mitochondria-targeting molecules as anti-cancer agents.5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.Monoclonal antibody-induced cytokine-release syndrome.New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.Refractory chronic lymphocytic leukemia--new therapeutic strategies.Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia.Treatment of relapsed or refractory chronic lymphocytic leukemia.Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
P2860
Q24635408-B0536978-2EF5-4DFF-8F1B-F9D4C953955BQ26781895-50794053-E793-4BB5-B576-F1CA83F189B9Q27024061-8B4EA813-CA5C-4892-9FAF-34A69F39AB2FQ27024422-D070B804-0A96-4078-9FCA-EFBB6E363D3DQ28247489-2A399A20-6381-43E3-B2D5-00EFCC39ED75Q30353154-59D80647-6302-4D91-A8C9-B3E1EFC1B21EQ33379565-6979D280-440A-48E7-B354-916B18B79B7EQ33398808-0E944553-C75A-42A3-B8F2-0D5AE49DDBA0Q33406478-7C8F2B48-6976-4C24-BCC4-16D193B3C05CQ35029577-8166F5F3-9D3F-4E38-9A87-CD0B231810B6Q35033514-0B27A243-BA50-429A-8C1E-8364016F05C1Q35083049-334D162D-5395-4A62-903D-B4B00EC1BD8CQ35250940-AE3339DB-E483-4041-AF4A-2AB063E4A751Q35794457-39E281FE-32EB-4312-A9F4-4C7EAE45D9A4Q35860550-1B4A7D94-C09A-49C6-AB52-393577673056Q36284637-1FB734A4-4BD8-4D41-AA93-FAAFB6AAA2C4Q36429723-A234B4EC-BB8C-4FBA-955C-4E923A73A7B5Q36478849-65EA11D8-A58E-4526-A653-BE021F3CAD6AQ36501198-6BBBE4C7-A9CB-4F50-AB36-E1C125D7BD5DQ36512593-612B4765-BD33-4E37-B414-CB6FA4BF0020Q36541458-72305402-0185-485B-8280-172E16432764Q36611156-A0756193-F6CE-43D0-B793-309B65C152AAQ36612602-6E404083-6AF7-4A6D-AF62-CC6EB3E1AF56Q36726848-C880F2B7-D14F-4950-95E0-57A15F9DD693Q36862781-22315A30-9F81-4156-AEDD-53F37AADF767Q37136989-7DBC7BBB-FB5C-4E96-A418-B75DCBC96376Q37334965-599759FB-31DD-4E6F-9378-1C6F6D69C0ACQ37412148-B7354E77-5E59-4847-BEA9-6DD0B1CDC0A4Q37521403-526E6B0E-6E92-4610-B734-E62BA6BA774CQ37566211-E0594A05-7D39-4E5D-9F7D-09A2389AA0B8Q37648872-82D2FE56-7965-4A02-B525-63913F77C6F8Q37659067-F75095F9-C4D1-4FC0-B36F-85C55FFA01DAQ37755276-C527DEF9-EE56-422B-9B38-8736D9715E21Q37767703-1F69893A-D257-49A7-B70B-63AAF1C6D29CQ37840932-FE86B9FF-3582-46C2-8206-C3F7C8A68087Q37842484-8D264570-7C29-4E6E-BF2A-02D6422D0CCFQ37866341-37EB87BD-258B-4341-95C7-E4E96E956373Q37869144-8A339571-9572-47B6-92BF-47B5DEDEC5C6Q37964916-75DFA167-A8C6-4252-9005-C1A7C6B48948Q37997623-EBB68FD4-321B-490E-844C-32CC21F16658
P2860
Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Phase I to II multicenter stud ...... chronic lymphocytic leukemia.
@en
type
label
Phase I to II multicenter stud ...... chronic lymphocytic leukemia.
@en
prefLabel
Phase I to II multicenter stud ...... chronic lymphocytic leukemia.
@en
P2093
P921
P356
P1476
Phase I to II multicenter stud ...... d chronic lymphocytic leukemia
@en
P2093
Anatoliy K Golenkov
Charles C Cunningham
Kanti R Rai
Steven C Novick
Susan M O'Brien
P304
P356
10.1200/JCO.2005.02.4364
P407
P50
P577
2005-09-26T00:00:00Z